Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454350 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis
A Phase 4 study of Secondary Hyperparathyroidism, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00454350: Completed Phase 4 study of Secondary Hyperparathyroidism, sponsored by Genzyme, a Sanofi Company.
NCT00454350 is a Phase 4 study of Secondary Hyperparathyroidism that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 12 participants, below the 63-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00454350, a Phase 4 study of Secondary Hyperparathyroidism, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).
Conditions Studied
Interventions
- DRUG Hectorol (doxercalciferol injection)
- DRUG Zemplar (Paricalcitol injection)
Study Locations (1)
Minnesota
- - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
What the finished NCT00454350 record still lists
NCT00454350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 63-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Secondary Hyperparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Hectorol (doxercalciferol injection) is the first listed.
NCT00454350 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00454350 about?
NCT00454350 is a clinical study titled "A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis". This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).
What is the current status of trial NCT00454350?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2007-02. Estimated completion is 2007-07.
What conditions does trial NCT00454350 study?
This clinical trial studies the following conditions: Secondary Hyperparathyroidism.
What interventions are being tested in trial NCT00454350?
The interventions under investigation include: Hectorol (doxercalciferol injection) (DRUG), Zemplar (Paricalcitol injection) (DRUG).
Who is sponsoring clinical trial NCT00454350?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00454350 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Hyperparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00454350's enrollment target sits among peer trials
12 9th of 8 the lowest of 8 other Secondary Hyperparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Secondary Hyperparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial to Optimize Mineral Outcomes in Dialysis Patients
COMPLETED · Phase 4
-
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
COMPLETED · Phase 4
-
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
COMPLETED · Phase 4
-
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
COMPLETED · Phase 4
-
Precision Medicine Approaches to Renal Osteodystrophy
RECRUITING
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia